<DOC>
	<DOCNO>NCT01276106</DOCNO>
	<brief_summary>This 24-week randomized placebo-controlled study investigate effect oral IL-1beta inhibitor AC-201 patient type 2 diabetes mellitus already treat different background diabetes therapy .</brief_summary>
	<brief_title>Study AC-201 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Understanding study procedure agreement participate study give write informed consent Males females age 20 75 year , inclusive HbA1c ≥7.5 % ≤10 % BMI ≤45 kg/m2 FPG ≤270 mg/dL Diagnosis type 2 diabetes mellitus ≥6 month On stable regimen oral antidiabetic medication ≥3 month Willingness maintain stable diet exercise throughout study Willingness maintain current doses/regimens vitamin dietary supplement throughout study Female patient childbearing potential female partner male patient must willing use adequate contraception study . All female childbearing potential must negative urine pregnancy test screening . History type 1 diabetes and/or history ketoacidosis History diabetic neuropathy result significant functional impairment and/or require active medical surgical management , include chronic pain syndrome , gastroparesis , skin ulceration , amputation History longterm therapy insulin ( &gt; 30 day ) within 1 year screening ; Pregnancy lactation Current treatment follow medication within 2 month screen Anti inflammatory drug , include chronic daily use systemic corticosteroid ( aspirin ≤325 mg per day allow ) IL1 modulators : anakinra rilonacept Immunosuppressive drug : TNF inhibitor IL6 monoclonal antibody History severe hypoglycemic episode within 6 month screen Hypersensitivity AC201 anthraquinone derivative Surgery within 30 day prior screen Serum creatinine &gt; 1.5 mg/dL male &gt; 1.4 mg/dL female Presence cancer history cancer within past 5 year basal squamous cell carcinoma skin carcinoma situ cervix Advanced stage heart failure : New York Heart Association Class III IV cardiac status hospitalization congestive heart failure History unstable angina , myocardial infarction , uncontrolled arrhythmia , cerebrovascular accident , transient ischemic attack , revascularization , include percutaneous transluminal coronary angioplasty , within 6 month screen Uncontrolled hypertension ( define systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 100 mmHg ≥3 assessment screen ) Known infected human immunodeficiency virus ( HIV ) History acquire immune deficiency syndrome History TB , active TB ( pulmonary , extrapulmonary , military ) , positive test TB confirm PA chest xray within 6 month prior screen History acute infection EpsteinBarr Virus ( EBV ) , cytomegalovirus ( CMV ) , hepatitis C virus ( HCV ) within 4 week prior screen History chronic active ( latent ) hepatitis B virus , HCV , CMV infection ; History drug alcohol abuse Aspartate aminotransferase &gt; 3 × upper limit normal ( ULN ) alanine aminotransferase &gt; 3 × ULN screen Total bilirubin &gt; 1.5 × ULN screen Triglycerides &gt; 500 mg/dL screen Poor mental function reason expect patient difficulty comply study requirement Acute infection may affect blood glucose control within 4 week prior screen Known bilateral renal artery stenosis , patient solitary kidney , post renal transplant History autoimmune disease collagen vascular disease History hyperthyroidism hypocorticism Participation AC201 study within 1 year prior screen Participation investigational drug study within 30 day prior screen Any serious disease , opinion investigator , might pose risk patient make participation patient 's best interest .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>AC-201</keyword>
	<keyword>Interleukin 1 inhibitor</keyword>
</DOC>